Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Child Health and Disorders/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Child Infection and Immunity/Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China
Abstract Objective To study the expression of V-domain Ig suppressor of T cell activation (VISTA) in peripheral blood of children with juvenile idiopathic arthritis (JIA) and its role in the pathogenesis of JIA. Methods In this prospective study, peripheral blood was collected from 47 children with different subtypes of JIA and 10 healthy children. Flow cytometry was used to measure the expression levels of VISTA, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) on CD14+ mononuclear cells, CD4+ T lymphocytes, and CD8+ T lymphocytes. Results The children with JIA had a significantly lower expression level of VISTA than the healthy children (P<0.05). There was a significant difference in the expression of VISTA between the children with different subtypes of JIA, with the lowest expression level in those with systemic JIA (P<0.05). There was also a significant difference in the expression of VISTA between different immune cells, with a significantly higher expression level on the surface of monocytes (P<0.05). Correlation analysis showed that VISTA was negatively correlated with the expression of IFN-γ and TNF-α on CD4+ T cells (r=-0.436 and -0.382 respectively, P<0.05), CD8+ T cells (r=-0.348 and -0.487 respectively, P<0.05), and CD14+ mononuclear cells (r=-0.582 and -0.603 respectively, P<0.05). Conclusions The insufficient expression of VISTA may be associated with the pathogenesis of JIA, and enhancing the immunomodulatory effect of VISTA might be one option for the treatment of JIA in the future.
XIAO Li-Ping,ZHOU Li-Na,CHEN Jun-Jie et al. A preliminary study on the role of V-domain Ig suppressor of T cell activation in juvenile idiopathic arthritis[J]. CJCP, 2023, 25(3): 272-277.
XIAO Li-Ping,ZHOU Li-Na,CHEN Jun-Jie et al. A preliminary study on the role of V-domain Ig suppressor of T cell activation in juvenile idiopathic arthritis[J]. CJCP, 2023, 25(3): 272-277.
Lin YT, Wang CT, Gershwin ME, et al. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis[J]. Autoimmun Rev, 2011, 10(8): 482-489. PMID: 21320644. DOI: 10.1016/j.autrev.2011.02.001.
Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001[J]. J Rheumatol, 2004, 31(2): 390-392. PMID: 14760812.
Mezouar S, Mege JL. Changing the paradigm of IFN-γ at the interface between innate and adaptive immunity: macrophage-derived IFN-γ[J]. J Leukoc Biol, 2020, 108(1): 419-426. PMID: 32531848. DOI: 10.1002/JLB.4MIR0420-619RR.
Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics[J]. Int J Mol Sci, 2021, 22(5): 2719. PMID: 33800290. PMCID: PMC7962638. DOI: 10.3390/ijms22052719.
Xu W, Dong J, Zheng Y, et al. Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression[J]. Cancer Immunol Res, 2019, 7(9): 1497-1510. PMID: 31340983. PMCID: PMC6726548. DOI: 10.1158/2326-6066.CIR-18-0489.
